Samir and Arjun Udani’s ₦50 Billion Bet on MeCure | issue 141

Samir and Arjun Udani’s ₦50 Billion Bet on MeCure

Explores the ambitious growth story behind one of Nigeria’s healthcare and pharmaceutical businesses and the investment strategy shaping its next phase.

The cover story features Samir and Arjun Udani and examines their ₦50 billion bet on MeCure, the thinking behind the investment and the opportunity they see in Nigeria’s rapidly evolving healthcare market. The edition looks at MeCure’s role in pharmaceutical manufacturing, healthcare distribution and access to essential medicines, while examining the business environment surrounding Nigeria’s healthcare industry.

Beyond the cover feature, this edition explores the challenges facing pharmaceutical companies operating in Nigeria. It examines the impact of foreign exchange volatility, rising production costs, infrastructure constraints, import dependence, regulatory requirements and the difficulty of building reliable supply chains in a market where access to affordable medicines remains a major concern.

Readers will also discover how local pharmaceutical manufacturing can create opportunities for businesses while strengthening healthcare supply chains. The magazine examines the economics of investing in production capacity, distribution networks and healthcare infrastructure, and why long-term capital can play an important role in expanding the sector.

The issue also looks at the wider business opportunities emerging across Nigeria’s healthcare ecosystem, from pharmaceutical manufacturing and distribution to technology, private investment and new approaches to improving access to healthcare products.

Designed for entrepreneurs, executives, investors, healthcare professionals and business leaders, this edition offers insights into the people, capital and strategy behind MeCure’s growth and the broader forces shaping the future of healthcare and pharmaceutical business in Africa.